Synergistic FLT3 Cancer Treatment System

A comprehensive system integrating crenolanib with AI, IoT, blockchain, and nanomaterials to treat FLT3 mutated proliferative disorders, enhancing treatment outcomes and patient monitoring.

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders. However, it lacked a comprehensive system for personalized treatment, real-time monitoring, and secure data storage. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.

The system comprises a crenolanib administration module, a patient monitoring module utilizing artificial intelligence to predict treatment outcomes, and a blockchain-based data storage module to securely store patient data. Additionally, the system may include a genomics analysis module using next-generation sequencing to identify FLT3 mutations, an IoT-based patient monitoring system to track treatment efficacy, and a nanomaterial-based delivery system to enhance bioavailability and target FLT3-positive cancer cells.

The new inventive concept combines crenolanib with AI, IoT, blockchain, and nanomaterials to create a synergistic system, which is not obvious from the original patent. The integration of these distinct technologies provides a non-obvious solution to the problem of personalized FLT3 cancer treatment.

Alternative embodiments may include the use of different AI algorithms, IoT devices, blockchain platforms, or nanomaterials. Variations may include the integration of additional technologies, such as machine learning or gene editing, to further enhance treatment outcomes.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the area of personalized cancer treatment. The system may be marketed to healthcare providers, pharmaceutical companies, and research institutions, offering a comprehensive solution for FLT3 cancer treatment.